Market Research Report

European hospital hand hygiene solutions market is estimated to record a healthy CAGR of 7.2% during the forecast period (2020-2026). Europe is one of the largest markets after the global hospital hand hygiene solutions market. It is growing at a healthy rate and is expected to grow at a similar pace during the forecast period. The rising awareness of using hospital hand hygiene solutions as essential safety equipment associated with treatment procedures of several diseases coupled with improved healthcare infrastructure, various favorable guidelines, and availability of technologically advanced medical devices for surgical procedures are driving the growth of the hospital hand hygiene solutions market in the region.   A full Report of  European Hospital Hand Hygiene Solutions Market  Available  at https://www.omrglobal.com/industry-reports/european-hospital-hand-hygiene-solutions-market   In addition, the pandemic outbreak has caused widespread deaths of h...

  The Asia-Pacific hospital hand hygiene solutions market is estimated to witness a strong CAGR of 8.6% during the forecast period (2020-2026). At present, the outbreak of COVID-19, which started in China and then moved globally, including in developed nations such as the US, is driving the higher production of preventative accessories, consisting of hand sanitizers and hand washes in Asia-Pacific countries, as the US economy largely depends on manufacturing and supply chains based in Asian countries, in particular China. Therefore, a rising patient pool, coupled with favorable healthcare infrastructure, is likely to fuel market growth in Asia-Pacific.  A full Report of  Asia-Pacific Hospital Hand Hygiene Solutions Market  Available  at https://www.omrglobal.com/industry-reports/asia-pacific-hospital-hand-hygiene-solutions-market   Furthermore, the healthcare system in this region is undergoing a rapid transformation with favorable support from various gove...

The Indian hospital hand hygiene solutions market is expected to exhibit a rapid CAGR of 9.2% during the forecast period (2020-2026). The outbreak of the COVID-19 pandemic resulted in an increasing demand for hand hygiene solutions in the country. Indian is one of the worst COVID-19 hit countries, with more than 8 million, till October 2020. In addition, the local government has made it mandatory for every individual to use sanitizers and disinfectants when outdoors. Amid the pandemic, the government of Indian has ramped up domestic manufacturing of PPE as well as hospital hand hygiene solutions for healthcare workers to meet the excessive demand. Thus, with the government’s support, Indian manufacturers have exponentially increased their production of hospital hand hygiene solutions. Further, with the government lifting the restrictions on exports of hospital hand hygiene solutions, the country is also catering to international demand, focusing more on exports. Recently, around 90% of...

  The Indian hospital hand hygiene solutions market is expected to exhibit a rapid CAGR of 9.2% during the forecast period (2020-2026). The outbreak of the COVID-19 pandemic resulted in an increasing demand for hand hygiene solutions in the country. Indian is one of the worst COVID-19 hit countries, with more than 8 million, till October 2020. In addition, the local government has made it mandatory for every individual to use sanitizers and disinfectants when outdoors. Amid the pandemic, the government of Indian has ramped up domestic manufacturing of PPE as well as hospital hand hygiene solutions for healthcare workers to meet the excessive demand. Thus, with the government’s support, Indian manufacturers have exponentially increased their production of hospital hand hygiene solutions. Further, with the government lifting the restrictions on exports of hospital hand hygiene solutions, the country is also catering to international demand, focusing more on exports. Recently, around ...

  The  anticoccidial drugs market  is anticipated to grow at a modest CAGR of around 4% during the forecast period 2020-2026. Coccidiosis is a parasitic disease which is caused due to coccidian protozoa. The primary symptom of the disease includes diarrhea which may become bloody in severe cases. Coccidiosis is found in dogs, chickens, cattle, goats, and many other species. Sometimes, there is also a risk of transferring this disease to humans through dogs. Besides, it is one of the most common diseases among chickens, especially in young chickens.   A full Report of    Global Anticoccidial Drugs Market  is Available at:   https://www.omrglobal.com/industry-reports/anticoccidial-drugs-market     Increasing meat consumption is a key factor for the growth of the poultry industry all across the globe, which in turn will augment the demand of anticoccidial drugs. The US is the largest poultry market all across the globe. As per the...

  European cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.0% during the forecast period. Increasing launches of monoclonal antibodies biosimilars is offering an opportunity for market growth. For instance, in April 2020, Pfizer Inc. declared the European Commission approval of RUXIENCE (rituximab). It is a monoclonal antibody and biosimilar to MabThera (rituximab), which aims to treat granulomatosis with polyangiitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, rheumatoid arthritis, microscopic polyangiitis, and pemphigus vulgaris. The biosimilars' approval including RUXIENCE is an essential development to treat certain cancers and autoimmune conditions. It offers effectiveness to improve access to treatment access while minimizing healthcare costs.   A full Report of European cancer monoclonal Antibodies Market  Available at    https://www.omrglobal.com/industry-reports/european-cancer-monoclonal-antibodies-market   ...

  Asia-Pacific cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.2% during the forecast period. Increasing awareness regarding cancer is one of the pivotal factors accelerating market growth. Biopharmaceutical firms have reported the launch of public awareness campaigns for cancer. For instance, in May 2016 Roche launched a public awareness campaign known as ‘Run for Her’. This campaign aims to deliver successfully crucial messages regarding the need for breast cancer screening in women frequently. Early diagnosis and consistent treatment can lead to improving disease outcomes and quality of life of breast cancer patients.   A full Report of  Asia-Pacific Cancer Monoclonal Antibodies Market Available at   https://www.omrglobal.com/industry-reports/asia-pacific-cancer-monoclonal-antibodies-market   The company organized this campaign in collaboration with the China Cancer Rehabilitation Society, to increase public awareness regard...

  China cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.6% during the forecast period. An increasing launch of biosimilars has been witnessed in the country owing to the increasing focus on providing affordable cancer therapy in the country. For instance, in August 2020, China’s NMPA (National Medical Products Administration) approved a biosimilar version of Roche’s Herceptin (trastuzumab), Shanghai’s Henlius which is referred to as HLX02 to treat HER2-mutated cancers. As its reference product, this biosimilar is also used for the treatment of HER2-positive early breast cancer, metastatic gastric cancer, and metastatic breast cancer. This therapy was demonstrated to be very similar to Roche’s Herceptin regarding safety, efficacy, and quality in preclinical, Phase 1, and Phase 3 studies. It is expected that this therapy will benefit HER2-positive gastric cancer and breast cancer patients in China.  A full Report of  China Cancer Monoclonal Antibodi...

  The global cancer monoclonal antibodies market is estimated to grow at a CAGR of 9.8% during the forecast period. Significant research on monoclonal antibodies have been witnessed, which is providing a scope for the market growth. The availability of funding and the increasing focus of researchers and biopharmaceutical firms towards the development of monoclonal antibodies are some major factors driving the research on monoclonal antibodies. For instance, as per the Wellcome Trust, over 570 monoclonal antibodies are currently in clinical testing. In 2019, 7 of the 10 best-selling novel drugs were monoclonal antibodies for the treatment of cancer and inflammatory diseases.   A full Report of  Global Cancer Monoclonal Antibodies Market Available at   https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market   Additionally, the companies are collaborating for the development of novel monoclonal antibodies therapeutics for cancer. Fo...

  The global metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.8% during the forecast period. An increasing number of clinical trials have been witnessed over the years owing to the rising prevalence of metabolic disorders and increasing demand for more effective treatment. For instance, in May 2020, POXEL SA, a biopharmaceutical company focused to develop innovative treatments for metabolic disorders, such as non-alcoholic steatohepatitis (NASH) and type 2 diabetes declared new preclinical results for PXL770. It is a direct adenosine monophosphate-activated protein kinase(AMPK) activator, was assessed in a rodent NASH model along with other major agents in development, such as a thyroid receptor  agonist (MGL-3196), an FXR agonist (obeticholic acid), and a GLP-1 receptor agonist (semaglutide).   A full Report of  Global Metabolic Disorder Therapeutics Market Available at   https://www.omrglobal.com/industry-reports/metabolic-d...